{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:47:04Z","timestamp":1785422824618,"version":"3.56.0"},"reference-count":166,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res Clin Pract"],"abstract":"<jats:p>Objective: In a previous review, we summarized the safety of linezolid-containing\nregimens to treat rifampin-resistant\/multidrug-resistant tuberculosis (RR\/MDR-TB),\nunderscoring the persistent need for shorter and safer regimens. The objective of the\npresent study was to explore the safety and tolerability directly attributable to linezolid\nin regimens designed to treat RR\/MDR-TB in studies published between 2009 and\n2025. Methods: We searched PubMed\/MEDLINE, Embase, the Cochrane Central\nRegister of Controlled Trials, Scopus, and Web of Science for studies reporting on\nthe safety and tolerability of linezolid since it was introduced as a repurposed drug in\nthe treatment of tuberculosis. Results: A total of 22 studies (including 26 arms) were\nidentified, with a total of 3,014 patients. There was significant variation in geographic\ndistribution, sample size (range, 8-655), linezolid dose (range, 300-1,200 mg), duration,\nand other core variables. The pooled rate of favorable outcomes among cohort studies\n(cure or treatment completion) was = 80.1%. Hematologic disorders (including anemia,\nthrombocytopenia, and leukopenia, in 33.1%) and peripheral neuropathy (in 33.9%)\nwere the most common adverse events (AEs), followed by psychiatric and neurological\ndisorders (in 12.3%), myalgia (in 7.0%), optic neuropathy (in 7.8%), gastrointestinal\nevents (in 1.9%), ototoxicity (in 2.9%), and rash (in 1.0%). Serious AEs were rarely\nreported. Conclusions: Although the recommended linezolid-containing regimens are\nconsidered safe, linezolid still causes frequent and severe AEs. A new drug with similar\ncharacteristics but lower toxicity will significantly improve the safety of antituberculosis\nregimens, with improved adherence and treatment outcomes.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20250464","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:53:40Z","timestamp":1782924820000},"page":"e20250464","source":"Crossref","is-referenced-by-count":0,"title":["Safety and tolerability of linezolid to treat tuberculosis: a systematic review and meta-analysis"],"prefix":"10.36416","author":[{"given":"Mehrnaz","family":"Amiri","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034m2b326","id-type":"ROR","asserted-by":"publisher"}],"name":"Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdis","family":"Cheraghi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041yk2d64","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Ghafari","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034m2b326","id-type":"ROR","asserted-by":"publisher"}],"name":"Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Javad Nasiri","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034m2b326","id-type":"ROR","asserted-by":"publisher"}],"name":"Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Rossato Silva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041yk2d64","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hb4yd20","id-type":"ROR","asserted-by":"publisher"}],"name":"MGMA Health Care Consulting Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Centis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041yk2d64","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Villa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00wjc7c48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthu","family":"James","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05psg6c12","id-type":"ROR","asserted-by":"publisher"}],"name":"Sensata Technologies (Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Pontal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bs6ak67","id-type":"ROR","asserted-by":"publisher"}],"name":"Ente Ospedaliero Ospedali Galliera"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Battista Migliori","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00mc77d93","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti Clinici Scientifici Maugeri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref0","unstructured":"1. World Health Organization. Global tuberculosis report 2025. Geneva:"},{"key":"ref1","unstructured":"World Health Organization; 2025"},{"key":"ref2","unstructured":"2. Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas"},{"key":"ref3","unstructured":"S, Kuksa L, et al. Surveillance of adverse events in the treatment"},{"key":"ref4","unstructured":"of drug-resistant tuberculosis: first global report. Eur Respir J."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"2019;54(6):1901522. https:\/\/doi.org\/10.1183\/13993003.01522-2019","DOI":"10.1183\/13993003.01522-2019"},{"key":"ref6","unstructured":"3. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF,"},{"key":"ref7","unstructured":"Baghaei P, et al. Treatment correlates of successful outcomes in"},{"key":"ref8","unstructured":"pulmonary multidrug-resistant tuberculosis: an individual patient"},{"key":"ref9","unstructured":"data meta-analysis. Lancet. 2018;392(10150):821-34. https:\/\/doi."},{"key":"ref10","unstructured":"org\/10.1016\/S0140-6736(18)31644-1"},{"key":"ref11","unstructured":"4. Nasiri MJ, Amiri M, Cheraghi M, Silva DR, Sotgiu G, D\u2019Ambrosio L, et"},{"key":"ref12","unstructured":"al. 15-year trends in efficacy and effectiveness of treatment outcomes"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"in drug-resistant pulmonary TB. IJTLD Open. 2025;2(4):187-98.","DOI":"10.5588\/ijtldopen.24.0620"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5588\/ijtldopen.24.0620","DOI":"10.5588\/ijtldopen.24.0620"},{"key":"ref15","unstructured":"5. World Health Organization. WHO consolidated guidelines on"},{"key":"ref16","unstructured":"tuberculosis. Module 4: treatment - drug-resistant tuberculosis"},{"key":"ref17","unstructured":"treatment, 2022 update. Geneva: World Health Organization; 2022."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"6. Migliori GB, Tiberi S. WHO drug-resistant TB guidelines 2022:","DOI":"10.5588\/ijtld.22.0263"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"what is new? Int J Tuberc Lung Dis. 2022;26(7):590-1. https:\/\/doi.","DOI":"10.5588\/ijtld.22.0263"},{"key":"ref20","unstructured":"org\/10.5588\/ijtld.22.0263"},{"key":"ref21","unstructured":"7. Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis"},{"key":"ref22","unstructured":"R, et al. Delamanid-containing regimens and multidrug-resistant"},{"key":"ref23","unstructured":"tuberculosis: A systematic review and meta-analysis. Int J Infect"},{"key":"ref24","unstructured":"Dis. 2022;124 Suppl 1(Suppl 1):S90-S103 https:\/\/doi.org\/10.1016\/j."},{"key":"ref25","unstructured":"ijid.2022.02.043"},{"key":"ref26","unstructured":"8. Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B,"},{"key":"ref27","unstructured":"Goudarzi H, et al. Bedaquiline-containing regimens and multidrugresistant tuberculosis: a systematic review and meta-analysis. J Bras"},{"key":"ref28","unstructured":"Pneumol. 2022;48(2):e20210384. https:\/\/doi.org\/10.36416\/1806-"},{"key":"ref29","unstructured":"3756\/e20210384"},{"key":"ref30","unstructured":"9. Amiri M, Cheraghi M, Nasiri MJ, Silva DR, Sotgiu G, D\u2019Ambrosio L, et"},{"key":"ref31","unstructured":"al. Safety of treatment regimens for drug-resistant tuberculosis over"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"a 15-year period: a scoping review. IJTLD Open. 2026;3(4):208-217.","DOI":"10.5588\/ijtldopen.25.0728"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5588\/ijtldopen.25.0728","DOI":"10.5588\/ijtldopen.25.0728"},{"key":"ref34","unstructured":"10. World Health Organization. Definitions and reporting framework for"},{"key":"ref35","unstructured":"tuberculosis: 2013 revision. Geneva: World Health Organization;"},{"key":"ref36","unstructured":"2013 (updated December 2014 and January 2020); 2020"},{"key":"ref37","unstructured":"11. World Health Organization. Rapid communication: key changes to"},{"key":"ref38","unstructured":"the treatment of drug-resistant tuberculosis. Geneva: World Health"},{"key":"ref39","unstructured":"Organization; 2022"},{"key":"ref40","unstructured":"12. Shukla A, Badal A, Ansari S. Study on the Effectiveness and Safety of"},{"key":"ref41","unstructured":"Linezolid Dose Reduction in Multidrug-Resistant Tuberculosis. SSR"},{"key":"ref42","unstructured":"Inst Int J Life Sci. 2025;11(1):6822-32. https:\/\/doi.org\/10.21276\/SSRIIJLS.2025.11.1.31"},{"key":"ref43","unstructured":"13. Wang J, Xue Y, Nie W, Ma L, Chu N, Du Y. Safety and Tolerability of"},{"key":"ref44","unstructured":"Contezolid Versus Linezolid for Short-Term Treatment of RifampicinResistant Pulmonary Tuberculosis: A Randomized Controlled Study."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Infect Drug Resist. 2025;18:3307-15. https:\/\/doi.org\/10.2147\/IDR.","DOI":"10.2147\/IDR.S516991"},{"key":"ref46","unstructured":"S516991"},{"key":"ref47","unstructured":"14. Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam"},{"key":"ref48","unstructured":"Mahomed A, et al. An All-Oral 6-Month Regimen for MultidrugResistant Tuberculosis: A Multicenter, Randomized Controlled"},{"key":"ref49","unstructured":"Clinical Trial (the NExT Study). Am J Respir Crit Care Med."},{"key":"ref50","unstructured":"2022;205(10):1214-27. https:\/\/doi.org\/10.1164\/rccm.202107-"},{"key":"ref51","unstructured":"1779OC"},{"key":"ref52","unstructured":"15. Jing W, Wang Q, Wang J, Ma L, Huang M, Wang J, et al. New AllOral Short-term Regimen for Multidrug-Resistant Tuberculosis: A"},{"key":"ref53","unstructured":"Semi-randomized Controlled Trial Conducted in China. Open Forum"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Infect Dis. 2025;12(2):ofaf020. https:\/\/doi.org\/10.1093\/ofid\/ofaf020","DOI":"10.1093\/ofid\/ofaf020"},{"key":"ref55","unstructured":"16. Fu L, Weng T, Sun F, Zhang P, Li H, Li Y, et al. Insignificant"},{"key":"ref56","unstructured":"difference in culture conversion between bedaquiline-containing"},{"key":"ref57","unstructured":"and bedaquiline-free all-oral short regimens for multidrug-resistant"},{"key":"ref58","unstructured":"tuberculosis. Int J Infect Dis. 2021;111:138-47. https:\/\/doi."},{"key":"ref59","unstructured":"org\/10.1016\/j.ijid.2021.08.055"},{"key":"ref60","unstructured":"17. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM,"},{"key":"ref61","unstructured":"et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis."},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"N Engl J Med. 2020;382(10):893-902. https:\/\/doi.org\/10.1056\/","DOI":"10.1056\/NEJMoa1901814"},{"key":"ref63","unstructured":"NEJMoa1901814"},{"key":"ref64","unstructured":"18. Fu L, Zhang X, Xiong J, Sun F, Weng T, Li Y, et al. Selecting an"},{"key":"ref65","unstructured":"appropriate all-oral short-course regimen for patients with multidrugresistant or pre-extensive drug-resistant tuberculosis in China: A"},{"key":"ref66","unstructured":"multicenter prospective cohort study. Int J Infect Dis. 2023;135:101-"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"108. https:\/\/doi.org\/10.1016\/j.ijid.2023.08.001","DOI":"10.1016\/j.ijid.2023.08.001"},{"key":"ref68","unstructured":"19. Babu LP, Robin N, Babu JY, Jose J, George S. Adverse Drug"},{"key":"ref69","unstructured":"Reactions Among Drug-Resistant Tuberculosis Treatment: An"},{"key":"ref70","unstructured":"Observational Cohort Study. Int J Pharm Pharm Sci. 2021;13(9):50-"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"55. https:\/\/doi.org\/10.22159\/ijpps.2021v13i9.42460","DOI":"10.22159\/ijpps.2021v13i9.42460"},{"key":"ref72","unstructured":"20. McDowell A, Haas M, Seaworth B, Wilson JW, Patrawalla A, Haley"},{"key":"ref73","unstructured":"C, et al. Linezolid use for the treatment of multidrug-resistant"},{"key":"ref74","unstructured":"tuberculosis, TB centers of excellence, United States, 2013-2018."},{"key":"ref75","unstructured":"J Clin Tuberc Other Mycobact Dis. 2021;22:100201. https:\/\/doi."},{"key":"ref76","unstructured":"org\/10.1016\/j.jctube.2020.100201"},{"key":"ref77","unstructured":"21. Padayatchi N, Bionghi N, Osman F, Naidu N, Ndjeka N, Master I, et"},{"key":"ref78","unstructured":"al. Treatment outcomes in patients with drug-resistant TB-HIV coinfection treated with bedaquiline and linezolid. Int J Tuberc Lung"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Dis. 2020;24(10):1024-1031. https:\/\/doi.org\/10.5588\/ijtld.20.0048","DOI":"10.5588\/ijtld.20.0048"},{"key":"ref80","unstructured":"22. Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K. Adverse"},{"key":"ref81","unstructured":"drug reactions in South African patients receiving bedaquilinecontaining tuberculosis treatment: an evaluation of spontaneously"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"reported cases. BMC Infect Dis. 2019;19(1):544. https:\/\/doi.","DOI":"10.1186\/s12879-019-4089-x"},{"key":"ref83","unstructured":"org\/10.1186\/s12879-019-4197-7"},{"key":"ref84","unstructured":"23. Carroll MW, Lee M, Cai Y, Hallahan CW, Shaw PA, Min JH, et"},{"key":"ref85","unstructured":"al. Frequency of adverse reactions to first- and second-line antituberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis."},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"2012;16(7):961-6. https:\/\/doi.org\/10.5588\/ijtld.11.0574","DOI":"10.5588\/ijtld.11.0574"},{"key":"ref87","unstructured":"24. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina"},{"key":"ref88","unstructured":"A, et al. A retrospective TBNET assessment of linezolid safety,"},{"key":"ref89","unstructured":"tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"J. 2009;34(2):387-93. https:\/\/doi.org\/10.1183\/09031936.00009509","DOI":"10.1183\/09031936.00009509"},{"key":"ref91","unstructured":"25. Prajapati K, Mishra V, Desai M, Solanki R, Naik P. Treatment outcome"},{"key":"ref92","unstructured":"of patients having extensively drug-resistant tuberculosis in Gujarat,"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"India. Int J Mycobacteriol. 2017;6(3):289-95. https:\/\/doi.org\/10.4103\/","DOI":"10.4103\/ijmy.ijmy_59_17"},{"key":"ref94","unstructured":"ijmy.ijmy_59_17"},{"key":"ref95","unstructured":"26. Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R,"},{"key":"ref96","unstructured":"Anande L, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine"},{"key":"ref97","unstructured":"for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin"},{"key":"ref98","unstructured":"Infect Dis. 2022;76(3):e938-46."},{"key":"ref99","unstructured":"27. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and"},{"key":"ref100","unstructured":"safety in MDR- and XDR-TB: an Indian perspective. Eur Respir J."},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"2010;35(4):936-8. https:\/\/doi.org\/10.1183\/09031936.00132009","DOI":"10.1183\/09031936.00132009"},{"key":"ref102","unstructured":"28. Nguyen TMP, Le THM, Merle CSC, Pedrazzoli D, Nguyen NL, Decroo"},{"key":"ref103","unstructured":"T, et al. Effectiveness and safety of bedaquiline-based, modified"},{"key":"ref104","unstructured":"all-oral 9-11-month treatment regimen for rifampicin-resistant"},{"key":"ref105","unstructured":"tuberculosis in Vietnam. Int J Infect Dis. 2023;126:148-154. https:\/\/"},{"key":"ref106","unstructured":"doi.org\/10.1016\/j.ijid.2022.11.007"},{"key":"ref107","unstructured":"29. Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar"},{"key":"ref108","unstructured":"E, Wessels AM, et al. Comparison of the pharmacokinetics of"},{"key":"ref109","unstructured":"two dosage regimens of linezolid in multidrug-resistant and"},{"key":"ref110","unstructured":"extensively drug-resistant tuberculosis patients. Clin Pharmacokinet."},{"key":"ref111","unstructured":"2010;49(8):559-65. https:\/\/doi.org\/10.2165\/11532080-000000000-"},{"key":"ref112","unstructured":"00000"},{"key":"ref113","unstructured":"30. Mishra A, Mathur S, Jain S. A retrospective study of adverse drug"},{"key":"ref114","unstructured":"reaction in multidrug-resistant tuberculosis patients at tertiary care"},{"key":"ref115","unstructured":"hospital. Asian J Pharm Clin Res 2022;15(8):66-70. https:\/\/doi."},{"key":"ref116","unstructured":"org\/10.22159\/ajpcr.2022.v15i8.45174"},{"key":"ref117","unstructured":"31. Boga M, Marukutira T, Murray A, Chan GG, Huang GK. Tolerability"},{"key":"ref118","unstructured":"of linezolid in patients with drug-resistant TB in Daru, Western"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Province, PNG. Public Health Action. 2024;14(4):158-163. https:\/\/doi.","DOI":"10.5588\/pha.24.0041"},{"key":"ref120","unstructured":"org\/10.5588\/pha.24.0041"},{"key":"ref121","unstructured":"32. Letswee G, Kamau H, Gaida R, Truter I. Haematological adverse"},{"key":"ref122","unstructured":"effects associated with linezolid in patients with drug-resistant"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"tuberculosis: an exploratory study. Int J Pharm Pract. 2019;27(6):575-","DOI":"10.1111\/ijpp.12543"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"7. https:\/\/doi.org\/10.1111\/ijpp.12543","DOI":"10.1111\/ijpp.12543"},{"key":"ref125","unstructured":"33. Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van"},{"key":"ref126","unstructured":"der Werf TS, et al. Linezolid tolerability in multidrug-resistant"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"tuberculosis: a retrospective study. Eur Respir J. 2015;46(4):1205-7.","DOI":"10.1183\/13993003.00606-2015"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1183\/13993003.00606-2015","DOI":"10.1183\/13993003.00606-2015"},{"key":"ref129","unstructured":"34. Hasan T, Medcalf E, Nyang\u2019wa BT, Egizi E, Berry C, Dodd M, et"},{"key":"ref130","unstructured":"al. The Safety and Tolerability of Linezolid in Novel Short-Course"},{"key":"ref131","unstructured":"Regimens Containing Bedaquiline, Pretomanid, and Linezolid to"},{"key":"ref132","unstructured":"Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data"},{"key":"ref133","unstructured":"Meta-analysis. Clin Infect Dis. 2024;78(3):730-741. https:\/\/doi."},{"key":"ref134","unstructured":"org\/10.1093\/cid\/ciad653"},{"key":"ref135","unstructured":"35. Jaspard M, Butel N, El Helali N, Marigot-Outtandy D, Guillot H,"},{"key":"ref136","unstructured":"Peytavin G, et al. Linezolid-Associated Neurologic Adverse Events in"},{"key":"ref137","unstructured":"Patients with Multidrug-Resistant Tuberculosis, France. Emerg Infect"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Dis. 2020;26(8):1792-1800. https:\/\/doi.org\/10.3201\/eid2608.191499","DOI":"10.3201\/eid2608.191499"},{"key":"ref139","unstructured":"36. Tse-Chang A, Kunimoto D, Der E, Ahmed R. Assessment of linezolid"},{"key":"ref140","unstructured":"efficacy, safety and tolerability in the treatment of tuberculosis:"},{"key":"ref141","unstructured":"A retrospective case review. Can J Infect Dis Med Microbiol."},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"2013;24(3):e50-2. https:\/\/doi.org\/10.1155\/2013\/535616","DOI":"10.1155\/2013\/535616"},{"key":"ref143","unstructured":"37. Kim HY, Srivastava S, Ak HK, Marais BJ, Alffenaar JW. Optimal Dose"},{"key":"ref144","unstructured":"or Optimal Exposure? Consideration for Linezolid in Tuberculosis"},{"key":"ref145","unstructured":"Treatment. Antimicrob Agents Chemother. 2020;64(7):e00287-20."},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1128\/AAC.00287-20","DOI":"10.1128\/AAC.00287-20"},{"key":"ref147","unstructured":"38. Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely"},{"key":"ref148","unstructured":"M. Therapeutic Drug Monitoring Can Improve Linezolid Dosing"},{"key":"ref149","unstructured":"Regimens in Current Clinical Practice: A Review of Linezolid"},{"key":"ref150","unstructured":"Pharmacokinetics and Pharmacodynamics. Ther Drug Monit."},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"2020;42(1):83-92. https:\/\/doi.org\/10.1097\/FTD.0000000000000710","DOI":"10.1097\/FTD.0000000000000710"},{"key":"ref152","unstructured":"39. Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange"},{"key":"ref153","unstructured":"WC, et al. Simple strategy to assess linezolid exposure in patients"},{"key":"ref154","unstructured":"with multi-drug-resistant and extensively-drug-resistant tuberculosis."},{"key":"ref155","unstructured":"Int J Antimicrob Agents. 2017;49(6):688-94. https:\/\/doi.org\/10.1016\/j."},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"ijantimicag.2017.01.017","DOI":"10.1088\/1475-7516\/2017\/01\/017"},{"key":"ref157","unstructured":"40. Metarfi Y, Chellal W, Ben Khadda Z, Hoummani H, Amara B, Achour"},{"key":"ref158","unstructured":"S. Therapeutic drug monitoring in anti-tuberculosis treatment: a"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"systematic review. J Antimicrob Chemother. 2025;80(6):1508-1518.","DOI":"10.1093\/jac\/dkaf126"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jac\/dkaf126","DOI":"10.1093\/jac\/dkaf126"},{"key":"ref161","unstructured":"41. Quncuo C, Ye WD, Yang J, He JQ. Predictors of therapeutic exposure"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"and pharmacokinetic variability of second-line anti-TB drugs in MDRTB patients: a retrospective study. Infection. 2025;53(6):2717-2726.","DOI":"10.1007\/s15010-025-02620-x"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s15010-025-02620-x","DOI":"10.1007\/s15010-025-02620-x"},{"key":"ref164","unstructured":"42. World Health Organization (WHO). Active TB Drug-Safety Monitoring"},{"key":"ref165","unstructured":"and Management (aDSM). Geneva: World Health Organization; 2015."}],"container-title":["Respiratory Research &amp; Clinical Practice"],"original-title":[],"link":[{"URL":"https:\/\/www.ithenticate.com\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:58:29Z","timestamp":1782925109000},"score":1,"resource":{"primary":{"URL":"https:\/\/rrcpjournal.org\/article\/safety-and-tolerability-of-linezolid-to-treat-tuberculosis-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":166,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20250464","relation":{},"ISSN":["3086-3910"],"issn-type":[{"value":"3086-3910","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"2025-0464"}}